Articles tagged with Fatty Liver Disease
A study published in the American Journal of Roentgenology found that multiparametric CT findings can distinguish patients with high-risk NAFLD, characterized by advanced fibrosis or cirrhosis. However, the presence of nonalcoholic steatohepatitis (NASH) remains elusive on CT.
The study found that the green Mediterranean diet resulted in the greatest reduction of hepatic fat, with participants experiencing dramatic reductions in fatty liver. The modified diet included high intake of walnuts and Mankai, as well as less red meat.
Researchers found that a protein called Cx43 allows stress signals from one liver cell to spread to neighboring cells, causing dysfunction. Mice with deleted Cx43 were protected from insulin resistance, glucose intolerance, and non-alcoholic fatty liver disease.
A new study suggests a link between low levels of glycine and nonalcoholic fatty liver disease (NAFLD), potentially leading to novel treatment options. Researchers found that improving body composition and glutathione synthesis with a tripeptide called DT-109 could attenuate experimental NAFLD.
Researchers found that triclosan disrupts metabolism and the gut microbiome, leading to accelerated development of fatty liver and fibrosis. The study provides new insights into risk factors for non-alcoholic fatty liver disease (NAFLD) in humans.
Researchers will investigate the role of Cyp2b genes, human CYP2B6 gene, and environmental toxicants like PFOS in obesity and fatty liver disease. The study aims to understand complex interactions between diet, fat stores, and genetic factors.
A recent study by University of Jyväskylä researchers found that a dietary supplement increased the growth of good bacteria in rats' gut, leading to reduced liver fat content and improved glucose metabolism. Preliminary results from human studies with fatty liver disease patients also seem promising.
A nationwide cohort study has confirmed that non-alcoholic fatty liver disease (NAFLD) is associated with increased mortality risk, even in mild stages. The study found that patients with NAFLD had a 93% increased risk of all-cause mortality, driven primarily by deaths from extra-hepatic cancer and cirrhosis.
Yale researchers found a molecular connection between nonalcoholic fatty liver disease and liver insulin resistance. They identified diacylglycerols and ceramides as key players in this process.
A new study found that obesity-related illnesses frequently occur in people with a BMI over 30, yet only 9% had obesity recorded as a cause of death. Researchers argue that obesity is not being accurately documented on medical certificates, highlighting the need for further studies.
A pilot study found that assessing liver fibrosis in people with type 2 diabetes could identify large numbers of previously undiscovered cases of advanced liver disease, increasing diagnosis rates 5-fold. The study also discovered that over half of patients diagnosed with significant fibrosis had normal ALT levels.
Children born to obese mothers face higher risk of developing non-alcoholic fatty liver disease due to microbiome disruption, which can be influenced by maternal diet during pregnancy. The study aims to investigate the role of pyrroloquinoline quinone in improving the microbiome and lowering the risk for NAFLD.
New studies demonstrate significant reductions in ALT, hepatic fat, and liver damage biomarkers for patients with non-alcoholic steatohepatitis (NASH). The treatments target lipid metabolism and show potential to address type 2 diabetes and obesity.
A study published in JCI Insight has identified a potential treatment for non-alcoholic fatty liver disease (NAFLD), with tesamorelin reducing liver fat and fibrosis progression. The drug appears to increase expression of genes associated with burning of fat in the mitochondria, which may prevent fibrosis.
A new study published in Nature Metabolism suggests that excessive fructose consumption can lead to a leaky gut and subsequently cause fatty liver disease. The researchers found that the high fructose corn syrup disrupts the epithelial barrier protecting internal organs from bacterial toxins, leading to chronic inflammatory conditions.
Researchers developed a new microscopy technique to visualize NAFLD progression in real-time, capturing details of lipid accumulation and immune cell behavior. The approach provides a highly useful research tool for identifying key parameters contributing to the disease.
A high-protein diet with a calorie-reduced intake was found to decrease liver fat by around 40% in obese individuals with non-alcoholic fatty liver disease. The study suggests that the positive effect of the high-protein diet is due to suppressed uptake, storage, and synthesis of fat in the liver.
A review article suggests postmenopausal women are at higher risk for developing nonalcoholic fatty liver disease (NAFLD) due to the decline in estrogen levels. Normal-weight women with normal lipid, glucose, and insulin levels are at low risk for NAFLD.
Researchers at UPV/EHU University of the Basque Country discover osteopontin's protective role in preventing early onset of metabolic fatty liver disease. Maintaining physiological levels of osteopontin is essential to delay disease progression during ageing.
Non-alcoholic fatty liver disease (NAFLD) affects both obese and non-obese individuals, with distinct differences found in male and female patients of varying body mass indexes. Key findings include lower skeletal muscle mass and insulin resistance in non-obese NAFLD patients compared to their obese counterparts.
A Wayne State University team has made significant breakthroughs in understanding the causal relationships between nonalcoholic fatty liver disease (NAFLD), type-2 diabetes, and obesity. They discovered two subtypes of NAFLD: one caused by genetic factors and another driven by metabolic syndrome.
Australian experts warn of a surge in chronic liver disease due to alcohol misuse and obesity-related liver disease. The number of cases has increased three-fold over the past 10-15 years, with over 6 million Australians affected.
Researchers have discovered a new target and therapy to fight NAFLD, a major health issue affecting 25% of the world population. Using siRNA to silence MCJ protein, they found reduced liver steatosis and fibrosis in preclinical mouse models.
A recent study reveals the cause behind the link between non-alcoholic fatty liver disease and neurological problems, including Alzheimer's disease-like symptoms. The unique role of an adipokine called Lipocalin-2 in causing neuroinflammation may explain the prevalence of MAFLD among individuals with neurological disorders.
A new study uses stool microbiomes to predict cirrhosis risk in patients with nonalcoholic fatty liver disease. Researchers found a unique signature that distinguishes cirrhosis from other causes of the disease, potentially leading to an accurate, non-invasive diagnostic tool.
A Phase II trial found that the treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression to non-alcoholic steatohepatitis. The study showed robust reduction in liver fat without corresponding increases in blood lipids.
A new study found that fecal transplants can reduce intestinal permeability in patients with non-alcoholic fatty liver disease (NAFLD), a condition associated with metabolic syndrome and autoimmune diseases. The treatment shows promise for improving gut health and preventing further inflammation.
Women with non-alcoholic fatty liver disease (NAFLD) in pregnancy face increased risks of maternal and infant health complications. The study found that NAFLD is associated with hypertensive complications, preterm birth, and maternal bleeding after delivery, independent of other metabolic diseases.
Researchers found an unexpected connection between electron imbalance in liver cells and many metabolic problems, including cardiovascular disease and fatty liver disease. The study identified a biomarker, alpha-hydroxybutyrate, to test for reductive stress and suggests LbNOX as a potential treatment.
Scientists from GIST developed a novel peripheral serotonin antagonist, which showed promising results in obese mice with impaired liver function. The compound improved symptoms of fatty liver disease and reduced body fat. Researchers hope the drug candidate will offer relief to patients with nonalcoholic fatty liver disease.
Researchers have identified three new genes that play a role in preventing fatty liver development. The genes IRGM, Ifgga2, and Ifgga4 produce regulatory proteins that counteract fat accumulation in the liver, but genetic variations lead to reduced protein production, resulting in increased fat content.
Recent studies on NAFLD have made significant progress in understanding the risk factors, diagnosis, and treatment of the condition. The latest research emphasizes the importance of gut microbiota modulation to improve severity, as well as the role of hepatic inflammatory pathways in driving comorbidities.
NAFLD affects 5.7% of adults in the US, progressing to cirrhosis in 39% over 8 years, with risk factors including cardiovascular disease and high cholesterol.
A new study led by Dr. Rohit Kohli shows that stevia extract can reduce markers of fatty liver disease, improving glucose levels and reducing cellular stress. The findings suggest potential benefits for pediatric patients with non-alcoholic fatty liver disease.
A study published at Digestive Disease Week found that nearly 83% of 9/11 first responders had fatty liver disease, compared to 24-45% in the general population. The research highlights the link between toxin exposure and non-alcoholic fatty liver disease among first responders.
Researchers from Joslin Diabetes Center have identified a potential early biomarker for non-alcoholic fatty liver disease (NAFLD), which is linked to the regulation of liver fat metabolism and fibrosis. The protein NREP was found to decrease in levels as NAFLD progressed, suggesting its role as an early indicator of the disease.
Researchers found that bariatric surgery significantly decreased liver enzymes, Fatty Liver Index, and BARD score in patients with NAFLD. Gastric bypass was associated with the greatest reduction in liver damage.
Researchers redefine Non-Alcoholic Fatty Liver Disease (NAFLD) as Metabolic Associated Fatty Liver Disease (MAFLD), a condition characterized by liver fat build-up affecting over 1 billion people. The new definition aims to improve treatment pathways, trial design, and drug development for this disease.
A ketogenic diet reduced liver fat content and improved insulin resistance in overweight participants. The diet also increased hydrolysis of triglycerides and promoted ketogenesis, suggesting a possible mechanism for reversing nonalcoholic fatty liver disease.
Yale scientists have discovered the molecular mechanisms that trigger metabolic imbalance between glucose production and energy utilization in the liver. They found that a protein called INSP3R1 regulates both gluconeogenesis and fat oxidation in response to glucagon, providing new insights into glucagon biology.
A novel cause of fatty liver disease has been discovered in lean individuals undergoing immune checkpoint blockade therapy. Researchers report a case of a woman who experienced severe inflammation of her subcutaneous fat and developed nonalcoholic fatty liver disease after treatment with the PD-1 inhibitor Nivolumab.
A recent study published in the journal AIDS found that vitamin E improves liver function and reduces fat in patients with nonalcoholic steatohepatitis (NASH) and HIV. The treatment was well-tolerated and showed more significant improvements than reported in the general population.
Researchers found that green tea extract and exercise reduced fatty liver deposits by 75% in mice fed a high-fat diet, suggesting a potential health strategy for people. The study also showed increased gene expression related to energy metabolism in mice treated with both green tea extract and exercise.
Researchers have discovered that indole, a natural compound found in gut bacteria and cruciferous vegetables, can reduce inflammation and fatty deposits in the liver. This study provides hope for new treatments and preventive measures for non-alcoholic fatty liver disease (NAFLD).
Researchers developed a small molecule drug CTPI-2 that targets Slc25a1 gene involved in lipid and glucose metabolism, preventing liver damage, obesity and glucose intolerance in mice. The study showed promising results, confirming the importance of this gene in fatty liver disease.
A UK study found that over 20% of young adults have fatty liver disease, with those who are overweight or obese at greatest risk. The research highlights the need for improved liver health awareness and management among this age group.
SIRT6, a longevity protein, plays a crucial role in burning and regulating liver fat metabolism. By activating PPAR-alpha, it promotes fat burning and protects against fatty liver and obesity-related damage.
A new study found that people with non-alcoholic fatty liver disease have lower physical work capacity due to a functional iron deficiency, which impairs energy production. The research suggests focusing on improving iron availability through diet may be more effective than exercise in addressing the condition.
A new study published in Cancer Research found that excess fat in the liver impairs a tumor-suppressing protein named HNF4α, increasing cancer risk. The research provides potential mechanisms for the growing incidence of liver cancer linked to fatty liver disease.
Researchers found that tesamorelin reduced liver fat and prevented liver fibrosis in people living with HIV. The study showed a 37% relative reduction in liver fat fraction and a significant decrease in blood markers associated with inflammation and liver damage.
A new therapy shows promise in reducing liver fat and fibrosis in people with HIV, a form of non-alcoholic fatty liver disease (NAFLD). The study found that tesamorelin reduced liver fat by 37% and slowed the progression of fibrosis in treated subjects.
Researchers found a significant association between psoriasis and non-alcoholic fatty liver disease (NAFLD) severity, with higher psoriasis severity linked to more severe hepatic damage. The study suggests that patients with both conditions should be closely monitored and managed to prevent worsening of both diseases.
The prevalence of NAFLD is rising due to a preventable epidemic, with over half of adults and one third of children classified as overweight or obese. The condition is linked to lack of physical activity, excess calorie intake, and sugary drinks.
Researchers discovered that a common type of gut bacteria, Klebsiella pneumoniae, produces high levels of alcohol in the body and can cause liver damage even in non-drinkers. The study found that 60% of patients with non-alcoholic fatty liver disease (NAFLD) had high- and medium-alcohol-producing K. pneumonia in their gut.
Researchers found that microcystin can significantly amplify non-alcoholic fatty liver disease even at low levels. The toxin was processed differently in the kidneys of mice with pre-existing liver disease, suggesting a need for special preventative guidelines.
Researchers at Massachusetts General Hospital developed a lab-on-a-chip platform to study non-alcoholic fatty liver disease (NAFLD) progression. The platform allows for detailed studies of NAFLD's effects on liver cells and evaluates the potential of investigational drugs.
Researchers from The Westmead Institute for Medical Research have discovered how fatty liver disease develops in lean people. Lean patients tend to have worse outcomes due to an 'obesity-resistant' profile, despite having higher levels of bile acids and FGF19, which increase energy expenditure.
Researchers at the University of Pittsburgh School of Medicine have successfully grown genetically modified miniature human livers in a laboratory setting. These mini livers mimic non-alcoholic fatty liver disease progression and can be used to test therapeutics, providing a valuable tool for understanding and treating diseases.
Research from the University of Sydney found that electric fans lowered core temperature and cardiovascular strain in hot, humid conditions, but were detrimental in very hot, dry conditions. The study highlights the limitations of using heat index values to recommend fan use during heat waves.
Michelle Long, MD, MSc, assistant professor of medicine at Boston University School of Medicine, has been awarded a three-year, $495,000 Doris Duke Clinical Scientist Development Award to investigate the relationship between physical activity and NAFLD. The study aims to identify biomarkers of early disease and risk for progression.